Jytaglen Plus

Metformin Hydrochloride, the active ingredient in Jytaglen Plus, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, often in combination with other antidiabetic agents.

GNH USA supplies Jytaglen Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jytaglen Plus is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone. - Type 2 diabetes mellitus (add‑on to metformin): provides additional glucose reduction for patients inadequately controlled on metformin alone. - Type 2 diabetes mellitus (add‑on to sulfonylurea or insulin): enhances overall glycaemic control when combined with other glucose‑lowering agents.

Jytaglen Plus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, usually early in therapy. - Headache: occasional tension‑type headache. - Upper respiratory tract infection: nasopharyngitis symptoms. - Dizziness: transient light‑headedness. - Abdominal discomfort: mild cramping or bloating.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, angio‑edema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant clinical parameters.

- Renal function: evaluate eGFR to avoid accumulation and lactic acidosis risk. - Hepatic function: assess liver enzymes, as impairment may increase adverse events. - Cardiovascular status: monitor for heart failure exacerbation. - Concomitant hypoglycaemic agents: adjust doses to prevent severe hypoglycaemia. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Jytaglen Plus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Severe renal impairment: markedly increases metformin exposure and lactic acidosis risk. - Iodinated contrast agents: may precipitate acute kidney injury, necessitating temporary discontinuation. - Alcohol abuse: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened hypoglycaemia; dose adjustments may be required. - Diuretics (especially thiazides): may reduce renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin levels.